These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2977264)

  • 1. Long-term results of treating advanced prostatic cancer with the LH-RH analogue Zoladex.
    Beacock CJ
    Am J Clin Oncol; 1988; 11 Suppl 2():S115-6. PubMed ID: 2977264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical study of an LH-RH agonist (ICI 118.630, Zoladex) in the treatment of prostatic cancer.
    Mauriac L; Coste P; Richaud P; Lamarche P; Mage P; Bonichon F
    Am J Clin Oncol; 1988; 11 Suppl 2():S117-9. PubMed ID: 2977265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. U.K. trials of treatment for M1 prostatic cancer. The LH-RH analogue Zoladex vs. orchidectomy.
    Ryan PG; Peeling WB
    Am J Clin Oncol; 1988; 11 Suppl 2():S169-72. PubMed ID: 2977272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoladex treatment of symptomatic prostatic carcinoma.
    Holdaway IM; Ibbertson HK; Croxson MS; Harvey V; Boulton J; Knox BS
    Am J Clin Oncol; 1988; 11 Suppl 2():S123-6. PubMed ID: 2977267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new hormonal therapy for prostatic cancer: long-term clinical and hormonal response.
    Ahmed SR; Grant JB; Shalet SM; Howell A; Costello CB; Weatherson T; Blacklock NJ
    Br J Urol; 1986 Oct; 58(5):534-8. PubMed ID: 2946355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
    Kotake T; Usami M; Sonoda T; Matsuda M; Okajima E; Osafune M; Isurugi K; Akaza H; Saitoh Y
    Am J Clin Oncol; 1988; 11 Suppl 2():S108-11. PubMed ID: 2977262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodegradable sustained release formulation of the LH-RH analogue 'Zoladex' for the treatment of hormone-responsive tumours.
    Furr BJ; Hutchinson FG
    Prog Clin Biol Res; 1985; 185A():143-53. PubMed ID: 3162174
    [No Abstract]   [Full Text] [Related]  

  • 8. Simultaneous administration of a luteinizing hormone releasing hormone agonist and diethylstilbestrol in the initial treatment of prostatic cancer.
    Mahler C; Denis L
    Am J Clin Oncol; 1988; 11 Suppl 2():S127-8. PubMed ID: 2977268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
    Beacock CJ; Buck AC; Zwinck R; Peeling WB; Rees RW; Turkes A; Walker K; Griffiths K
    Br J Urol; 1987 May; 59(5):436-42. PubMed ID: 2954605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H).
    Geldof AA; de Voogt HJ; Rao BR
    Prostate; 1987; 11(3):281-90. PubMed ID: 2960958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testicular histology after treatment with LH-RH analogue for carcinoma of the prostate.
    Johansen TE; Ogreid P; Kjellevold K; Blom P
    Br J Urol; 1990 Apr; 65(4):376-8. PubMed ID: 2140282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Goserelin--another LH-RH analog for prostate cancer.
    Med Lett Drugs Ther; 1990 Nov; 32(830):102. PubMed ID: 1700261
    [No Abstract]   [Full Text] [Related]  

  • 13. Interim report of a randomized trial comparing Zoladex 3.6 mg depot with diethylstilbestrol 3 mg/day in advanced prostate cancer. The West Midlands Urology Research Group.
    Emtage LA; Trethowan C; Hilton C; Kelly K; Blackledge GR
    Am J Clin Oncol; 1988; 11 Suppl 2():S173-5. PubMed ID: 2977273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical efficacy of long-term treatment with LH-RH analogue, ICI 118630 (Zoladex), in prostatic cancer patients. The Zoladex Multicenter Study Group].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Nihsijima T; Aso Y; Araki T; Itatani H
    Hinyokika Kiyo; 1988 Nov; 34(11):2059-66. PubMed ID: 2977261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LH-RH analogue treatment for advanced prostate cancer.
    Alcini E; D'Addessi A; Destito A; Grasso G
    Am J Clin Oncol; 1988; 11 Suppl 2():S120-2. PubMed ID: 2977266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of advanced prostatic carcinoma with a depot LH-RH analog (ICI 118630)].
    Grifoni R; Pierangeli T
    Minerva Urol Nefrol; 1989; 41(1):5-10. PubMed ID: 2527415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
    Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
    Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid rise of serum testosterone following discontinuation of long term treatment of prostate carcinoma with an LHRH-agonist.
    Kreis W; Budman DR; Delli Bovi P; Vinciguerra V
    Onkologie; 1988 Dec; 11(6):292-3. PubMed ID: 2977219
    [No Abstract]   [Full Text] [Related]  

  • 20. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
    Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
    Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.